EICHORCondition: Advanced Solid Tumor · Sponsor: Daiichi Sankyo
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| City of Hope At Orange County Lennar Foundation Cancer Center | Irvine, California, United States | — |
| Sharp Memorial Hospital | San Diego, California, United States | — |
| Brcr Medical Center, Inc Dba Boca Raton Clinical Research | Plantation, Florida, United States | — |
| University of Hawaii At Manoa | Honolulu, Hawaii, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Memorial Sloan-Kettering Cancer Center (Mskcc) - New York | New York, New York, United States | — |
| Clinical Research Alliance | Westbury, New York, United States | — |
| Unc Hospitals | Chapel Hill, North Carolina, United States | — |
| The Cleveland Clinic Foundation | Cleveland, Ohio, United States | — |
| Providence Portland Medical Center | Portland, Oregon, United States | — |
| Mary Crowley Cancer Research Centers | Dallas, Texas, United States | — |
+ 23 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06244485